meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
1
mNSCLC - L1 - PDL1 positive
14
mNSCLC - L1 - TMB>10Mb
1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
gene alteration target therapy
EGFR gene alteration
osimertinib
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib alone
dacomitinib
erlotinib based treatment
erlotinib alone
erlotinib plus bevacizumab
erlotinib plus cisplatin and gemcitabine
erlotinib plus pemetrexed
erlotinib plus SoC
gefitinib based treatment
gefitinib alone
gefitinib plus BSC
gefitinib plus SoC
pemetrexed plus platin followed by maintenance gefitinib
SoC followed by gefitinib
naquotinib
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus paclitaxel
atezolizumab plus pemetrexed and platin
avelumab based treatment
avelumab alone
cemiplimab
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab and pemetrexed plus platin
pembrolizumab plus SoC
sintilimab based treatment
sintillimab plus SoC
sugemalimab based treatment
sugemalimab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
pembrolizumab plus ipilimumab
VEGF(R) inhibitor
ramucirumab
ramucirumab plus erlotinib
sorafenib
sorafenib and erlotinib
versus all
vs chemotherapy
vs antifolates
vs pemetrexed
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs gemcitabine
vs taxanes
vs docetaxel
vs paclitaxel
vs nab-paclitaxel
vs vinca alkaloids
vs vinorelbine
vs vinorelbine and platin
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs docetaxel plus platin
vs gemcitabine plus platin
vs paclitaxel plus carboplatin
vs carboplatin plus nab-paclitaxel
vs pemetrexed plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs HER inhibitor
vs EGFR inhibitor
vs erlotinib based treatment
vs placebo plus erlotinib
vs gefitinib based treatment
vs gefitinib alone
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs atezolizumab based treatment
vs atezolizumab plus carboplatin plus nab-paclitaxel
vs pembrolizumab based treatment
vs pembrolizumab alone
vs pembrolizumab plus placebo
vs pembrolizumab plus SoC
vs non active control
vs no additional treatment
vs placebo
vs placebo plus BSC
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs bevacizumab plus carboplatin and paclitaxel
vs bevacizumab plus gemcitabine and platin
vs sorafenib
vs sorafenib and gemcitabine
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network